Join GENFIT
GENFIT is a biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs.
About us
GENFIT is a biopharmaceutical company, pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful development of elafibranor from early-stage to a successful Phase 3 and commercial launch by Ipsen in Primary Biliary Cholangitis (PBC) in the USA and several European countries.
Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas:four programs in acute on chronic liver failure (ACLF) are in pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; two of them are expected to enter the clinical phase in 2026. A Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA).
GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on compartment B of Euronext’s regulated market in Paris (Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.
GENFIT at a glance
years of experience with teams based in Lille, Paris, Zurich & Boston
patent applications and granted patents comprised in our portfolio
scientific authors among our research team
Latest job offers
You have questions? Contact us!
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos France
+33 (0)3 20 16 40 00